Neil Gallagher - 10 Feb 2025 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Reporting relationship: President, Head of R&D
Issuer ticker: SNDX
Reported as of: 10 Feb 2025
Net transaction value: -$71,597
SEC form: 4
Accepted by SEC: 12 Feb 2025, 17:13:24 UTC
Prior SEC filing: 07 Feb 2025
Next SEC filing: 02 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Michael A. Metzger, as Attorney-in-Fact

Key filing fact

Neil Gallagher filed Form 4 for Syndax Pharmaceuticals Inc (SNDX) on 12 Feb 2025.

Key facts

This page summarizes Neil Gallagher's Form 4 filing for Syndax Pharmaceuticals Inc (SNDX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Feb 2025, 17:13.

Change

Previous filing in this sequence was filed on 07 Feb 2025.
Current net transaction value: -$71,597.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SNDX transaction

Common Stock

Sale

Transaction value: $71,597
Shares: -4,618
Change %: -5.1%
Price: $15.50
Shares after: 85,095
Date: 10 Feb 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.